IgA is necessary and sufficient to protect against norovirus infection 2258197

A Arya Ökten (Yale University) R Renata Filler (Yale University) Z Zhenhao Fang (Yale University) B Brieyanna McWilliams (Department of Medicine, University of Pennsylvania) J Jenna Muscat-Rivera (University of Pennsylvania) J Justin Kung (Yale University) I Ilze Mari O Olivi Gomes (Yale University) M Madeleine Mankowski (Yale University) A Ashwin Skelly (University of Pennsylvania) A Adam Williams (Northwestern University) S Stephanie Eisenbarth (Northwestern University) S Sidi Chen M Megan Baldridge (Washington University in St. Louis) S Sanghyun Lee T Timothy Nice (Oregon Health & Science University) C Christiane Wobus (University of Michigan) T Thomas Smith (University of Texas Medical Branch at Galveston) D Drew Weissman E Edward Krieder (University of Pennsylvania) J Joseph Craft (Yale University) C Craig Wilen (Yale University)

Abstract

Abstract Introduction Human norovirus (HNV) causes up to 700 million infections and 200,000 deaths each year, primarily affecting young children in low-resource settings. Despite this significant public health and economic impact, no licensed vaccines or anti-viral therapies exist for HNV. Several vaccine candidates are currently in advanced clinical trials, including virus-like particle (VLP), adenoviral (Ad5), and mRNA lipid nanoparticle (LNP) based vaccines. While these candidates show promise, none have demonstrated complete or long-term protection. The mechanisms underlying protective immunity to HNV remain poorly defined, posing a major barrier to rational vaccine design. Technical limitations make it challenging to directly interrogate mechanisms of HNV immunity, as there are no scalable cell culture, reverse genetics, or small animal models. Murine norovirus (MNV) is a genetically tractable model for HNV that shares many fundamental properties including minimal intestinal pathology, rare epithelial cell tropism, and fecal-oral transmission. Methods We used a panel of genetically and pharmacologically modified mice to investigate the correlates and cellular determinants of protection to MNV infection. Results T cell—dependent IgA is necessary to control MNV replication in the small intestine, whereas CD8+ T cells are dispensable. IgA plasma cells mediate protection from re-infection and dimeric IgA, but not monomeric, is sufficient to confer complete protection against MNV infection. In contrast, despite generating a robust systemic IgG response, systemic vaccination with the viral capsid protein (VP1) fails to protect mice, mirroring the recent failure of a systemic VLP vaccine in infants. Conclusion Our work shows that mucosal IgA is central to controlling norovirus infection in a murine model and provides important insights for rational vaccine design and HNV immunotherapeutics. Funding Source n/a Topic Categories Viral Immunology (VIR)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (22)

A

Arya Ökten

Yale University

R

Renata Filler

Yale University

Z

Zhenhao Fang

Yale University

B

Brieyanna McWilliams

Department of Medicine, University of Pennsylvania

J

Jenna Muscat-Rivera

University of Pennsylvania

J

Justin Kung

Yale University

I

Ilze Mari

O

Olivi Gomes

Yale University

M

Madeleine Mankowski

Yale University

A

Ashwin Skelly

University of Pennsylvania

A

Adam Williams

Northwestern University

S

Stephanie Eisenbarth

Northwestern University

S

Sidi Chen

M

Megan Baldridge

Washington University in St. Louis

S

Sanghyun Lee

T

Timothy Nice

Oregon Health & Science University

C

Christiane Wobus

University of Michigan

T

Thomas Smith

University of Texas Medical Branch at Galveston

D

Drew Weissman

E

Edward Krieder

University of Pennsylvania

J

Joseph Craft

Yale University

C

Craig Wilen

Yale University